The Peripheral Artery Occlusive Disease (PAOD) drugs in development market research report provides comprehensive information on the therapeutics under development for Peripheral Artery Occlusive Disease (PAOD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Peripheral Artery Occlusive Disease (PAOD). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Peripheral Artery Occlusive Disease (PAOD) and features dormant and discontinued products.
GlobalData tracks 51 drugs in development for Peripheral Artery Occlusive Disease (PAOD) by 45 companies/universities/institutes. The top development phase for Peripheral Artery Occlusive Disease (PAOD) is preclinical with 23 drugs in that stage. The Peripheral Artery Occlusive Disease (PAOD) pipeline has 49 drugs in development by companies and two by universities/ institutes. Some of the companies in the Peripheral Artery Occlusive Disease (PAOD) pipeline products market are: Karis Bio, G&P Bioscience and Beijing Tide Pharmaceutical.
The key targets in the Peripheral Artery Occlusive Disease (PAOD) pipeline products market include Hepatocyte Growth Factor, Prostaglandin E2 Receptor EP1 Subtype, and P2Y Purinoceptor 12.
The key mechanisms of action in the Peripheral Artery Occlusive Disease (PAOD) pipeline product include Hepatocyte Growth Factor Activator with four drugs in Phase II. The Peripheral Artery Occlusive Disease (PAOD) pipeline products include ten routes of administration with the top ROA being Intramuscular and 12 key molecule types in the Peripheral Artery Occlusive Disease (PAOD) pipeline products market including Small Molecule, and Cell Therapy.
Peripheral Artery Occlusive Disease (PAOD) overview
Peripheral artery occlusive disease (PAOD), also known as peripheral arterial disease (PAD), refers to a condition characterized by the narrowing or blockage of the arteries outside the heart, predominantly affecting the arteries in the legs. This narrowing occurs due to atherosclerosis, the buildup of plaque within the arterial walls, restricting blood flow to the limbs. Individuals with PAOD may experience symptoms primarily in the legs, such as intermittent claudication, which manifests as pain, cramping, or fatigue in the calf muscles during physical activity. The discomfort typically subsides with rest. In severe cases, decreased blood flow can cause pain even at rest, non-healing ulcers, and tissue damage, leading to gangrene. Several factors contribute to the development of peripheral artery occlusive disease, including smoking, diabetes, high blood pressure, high cholesterol levels, obesity, sedentary lifestyle, advanced age, and family history of cardiovascular disease.
For a complete picture of Peripheral Artery Occlusive Disease (PAOD)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
